Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.
As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...
The National Medical Products Administration (NMPA) has cleared the drug for triple-negative breast cancer (TNBC), making it ...
The New Republic on MSN3h
Big Pharma Is the Only Reason Anyone Still Dies From HIVWhile antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...
Zacks.com on MSN1h
RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal CarcinomaDr. Reddy’s Laboratories RDY announced that it has launched a biosimilar of Coherus BioSciences’ CHRS Loqtorzi (toripalimab) ...
$ 93.76 1.34 1.46% ...
Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal ...
Inside the plan to address the issues of exploitation and inequality facing development consultants. Plus, ahead of World ...
Digital preservation is not keeping up with the growth of scholarly knowledge. Recognizing its causes is the first step to securing records everywhere for future generations. At the interface ...
India has been re-elected to the UN Peacebuilding Commission for 2025-2026, reaffirming its commitment to global peace and stability. As a founding member and major contributor to UN Peacekeeping ...
Kamala Harris released a Thanksgiving video in which she and her husband, Doug Emhoff, shared their gratitude for family, friends, and service members. Social media users noted she wore the same ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback